Immunology

Autoimmune diseases are among the most common diseases in America, affecting more than 23.5 million people¹. It is an illness that causes the immune system to produce antibodies that attack the normal body tissue.² Glenmark is exploring new, potential first- and best-in-class treatments for serious autoimmune diseases.

Glenmark’s most advanced immunology candidate, GBR 830, is an investigational treatment intended for patients with moderate-to-severe atopic dermatitis (AD). AD is an autoimmune disorder and is the most common inflammatory skin disease, affecting up to 3% of the adult population globally, and its prevalence has increased 2-3 fold over the last decades³. Recent advances in the understanding and treatment of moderate-to-severe AD have included identification of molecules in the human immune system that activate the disease. GBR 830 is a first-in-class, monoclonal antibody designed to inhibit OX40, a costimulatory immune checkpoint receptor expressed on activated T cells and memory T cells. Costimulatory signals are essential for T cell activity, and binding between OX40 and OX40L is a biomarker for the severity of autoimmune diseases. The pathway leads to conversion of activated T cells into memory T cells, which promotes inflammation. In addition, regulatory T cells also contribute to inflammation, and OX40 signaling by these cells downregulates immune-suppressing functions. It is believed that GBR 830 inhibits the dual activities of OX40 and OX40L binding in both activated T cells and regulatory T cells, thus reducing inflammation associated with symptoms of AD.

Click here to view our innovative pipeline.